IP02-03: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel combination (NDV-01) in High-Risk NMIBC: Update with 9-month Complete Response Data

IP02-03: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel combination (NDV-01) in High-Risk NMIBC: Update with 9-month Complete Response Data

Friday, May 15, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
146A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!